Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

M. A Aloe Spiriti; R. Latagliata; P. Niscola; A. Cortelezzi; M. Francesconi; D. Ferrari; E. Volpe; M. Clavio; A. Grossi; M. Tambone Reyes; P. Musto; M. E. Mitra; A. Azzarà; D. Pagnini; G. D'Arena; A. Spadano; E. Balleari; P. Pecorari; E. Capochiani; E. De Biasi; D. Perego; B. Monarca; F. Pisani; G. Scaramella; M. C. Petti

doi:10.1007/s00277-004-0961-9

Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

M. A Aloe Spiriti, R. Latagliata, P. Niscola, A. Cortelezzi, M. Francesconi, D. Ferrari, E. Volpe, M. Clavio, A. Grossi, M. Tambone Reyes, P. Musto, M. E. Mitra, A. Azzarà, D. Pagnini, G. D'Arena, A. Spadano, E. Balleari, P. Pecorari, E. Capochiani, E. De BiasiD. Perego, B. Monarca, F. Pisani, G. Scaramella, M. C. Petti

Research output: Contribution to journal › Article › peer-review

Abstract

This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb ≤10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r =0.53, P

Original language	English
Pages (from-to)	167-176
Number of pages	10
Journal	Annals of Hematology
Volume	84
Issue number	3
DOIs	https://doi.org/10.1007/s00277-004-0961-9
Publication status	Published - Mar 2005

Keywords

Anemia
Epoetin
Fatigue
Myelodysplastic syndrome
Quality of life

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-004-0961-9

Cite this

Spiriti, M. A. A., Latagliata, R., Niscola, P., Cortelezzi, A., Francesconi, M., Ferrari, D., Volpe, E., Clavio, M., Grossi, A., Reyes, M. T., Musto, P., Mitra, M. E., Azzarà, A., Pagnini, D., D'Arena, G., Spadano, A., Balleari, E., Pecorari, P., Capochiani, E., ... Petti, M. C. (2005). Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology, 84(3), 167-176. https://doi.org/10.1007/s00277-004-0961-9

Spiriti, MAA, Latagliata, R, Niscola, P, Cortelezzi, A, Francesconi, M, Ferrari, D, Volpe, E, Clavio, M, Grossi, A, Reyes, MT, Musto, P, Mitra, ME, Azzarà, A, Pagnini, D, D'Arena, G, Spadano, A, Balleari, E, Pecorari, P, Capochiani, E, De Biasi, E, Perego, D, Monarca, B, Pisani, F, Scaramella, G & Petti, MC 2005, 'Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome', Annals of Hematology, vol. 84, no. 3, pp. 167-176. https://doi.org/10.1007/s00277-004-0961-9

@article{c5e2c406c00549af9b18fcc5ae115023,

title = "Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome",

abstract = "This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb ≤10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r =0.53, P ",

keywords = "Anemia, Epoetin, Fatigue, Myelodysplastic syndrome, Quality of life",

author = "Spiriti, {M. A Aloe} and R. Latagliata and P. Niscola and A. Cortelezzi and M. Francesconi and D. Ferrari and E. Volpe and M. Clavio and A. Grossi and Reyes, {M. Tambone} and P. Musto and Mitra, {M. E.} and A. Azzar{\`a} and D. Pagnini and G. D'Arena and A. Spadano and E. Balleari and P. Pecorari and E. Capochiani and {De Biasi}, E. and D. Perego and B. Monarca and F. Pisani and G. Scaramella and Petti, {M. C.}",

year = "2005",

month = mar,

doi = "10.1007/s00277-004-0961-9",

language = "English",

volume = "84",

pages = "167--176",

journal = "Revue d'h{\'e}matologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

AU - Spiriti, M. A Aloe

AU - Latagliata, R.

AU - Niscola, P.

AU - Cortelezzi, A.

AU - Francesconi, M.

AU - Ferrari, D.

AU - Volpe, E.

AU - Clavio, M.

AU - Grossi, A.

AU - Reyes, M. Tambone

AU - Musto, P.

AU - Mitra, M. E.

AU - Azzarà, A.

AU - Pagnini, D.

AU - D'Arena, G.

AU - Spadano, A.

AU - Balleari, E.

AU - Pecorari, P.

AU - Capochiani, E.

AU - De Biasi, E.

AU - Perego, D.

AU - Monarca, B.

AU - Pisani, F.

AU - Scaramella, G.

AU - Petti, M. C.

PY - 2005/3

Y1 - 2005/3

N2 - This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb ≤10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r =0.53, P

AB - This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb ≤10 g/dl. Epoetin alfa 40,000 IU was given subcutaneously twice weekly; after 4 weeks, the dose could be reduced to 40,000 IU weekly in patients achieving erythroid response. QOL was assessed using the functional assessment of cancer therapy-anemia (FACT-An) questionnaire. FACT-An scores increased on average by 7.5 after 4 weeks and by 8.8 after 8 weeks compared with baseline. FACT-An scores were positively associated with Hb values (r =0.53, P

KW - Anemia

KW - Epoetin

KW - Fatigue

KW - Myelodysplastic syndrome

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=13844313807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844313807&partnerID=8YFLogxK

U2 - 10.1007/s00277-004-0961-9

DO - 10.1007/s00277-004-0961-9

M3 - Article

C2 - 15592833

AN - SCOPUS:13844313807

SN - 0939-5555

VL - 84

SP - 167

EP - 176

JO - Revue d'hématologie

JF - Revue d'hématologie

IS - 3

ER -

Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this